Understanding and Treating Type 1 Diabetes with a New Immune Approach
Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes
This project explores a new way to stop the immune system from attacking insulin-producing cells in people with Type 1 Diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11123184 on NIH RePORTER |
What this research studies
Type 1 Diabetes happens when the body's immune system mistakenly destroys cells that make insulin. Current treatments haven't fully succeeded, so we need new ideas. Our team found that a special antibody, called TLR4-Ab, helped reverse Type 1 Diabetes in mice. We believe this antibody works by activating certain immune cells that can calm down the overactive immune response. We are now working to understand exactly how this antibody works and to develop similar antibodies for human use.
Who could benefit from this research
Good fit: This foundational research is not yet recruiting patients, but future studies may seek individuals with newly diagnosed or acute Type 1 Diabetes.
Not a fit: Patients with long-standing Type 1 Diabetes or those with complications unrelated to the autoimmune process may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to a new type of treatment that could potentially reverse or significantly improve Type 1 Diabetes in humans.
How similar studies have performed: While this specific antibody approach is novel for Type 1 Diabetes, similar immune-modulating therapies have been explored in other autoimmune conditions.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Ridgway, William M — University of California at Davis
- Study coordinator: Ridgway, William M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.